---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-24-018479"
form_type: "8-K"
ticker: "PGEN"
cik: "0001356090"
company_name: "PRECIGEN, INC."
filed_at: "2024-12-30T23:59:59+00:00"
generated_at: "2026-05-28T22:41:01.701975+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Precigen completes BLA submission for PRGN-2012 and raises $79M in private placement

## Summary
- Submitted BLA to FDA for PRGN-2012 (RRP), requesting priority review; 60-day review period to determine acceptance.
- Phase 1/2 pivotal study: >50% of patients achieved Complete Response; >85% had fewer surgeries in year post-treatment.
- Raised $79M gross from sale of 8% Series A Convertible Perpetual Preferred Stock and warrants to purchase 52.7M shares at $0.75.
- Investors include Randal Kirk, Patient Capital Management, Bill Miller; proceeds for working capital and general corporate purposes.
- Cash runway extends into 2026, beyond potential commercial launch in H2 2025 if PRGN-2012 is approved.

## SEC filing metadata
- accession: 0000950103-24-018479
- form_type: 8-K
- ticker: PGEN
- cik: 0001356090
- company_name: PRECIGEN, INC.
- filed_at: 2024-12-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 8.01, 3.02, 3.03, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356090/000095010324018479/0000950103-24-018479-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356090/000095010324018479/dp222802_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-24-018479
- JSON: https://secwatch.observer/filing/0000950103-24-018479.json
- Plain text: https://secwatch.observer/filing/0000950103-24-018479.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.